The page is the record's research on the issuer — no analyst, no rating, no view. # Xenon Pharmaceuticals Inc. (NASDAQ: XENE) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is Xenon Pharmaceuticals Inc., listed on NASDAQ under the ticker XENE, with ISIN US98420N1054. The LEI is not on the record (no GLEIF record with the exact legal name in jurisdiction US-A1). The security type is Corporate, the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is British Columbia, Canada. The issuer is listed and not halted. ## The disclosure read The record holds 88 filings in the twelve months to 2026-11-08, across 34 filing days. The median gap between filing days is 6 days, and the median latency from latest filing to record date is 2 days for this issuer. The NASDAQ exchange medians are 6.0 days for cadence and 5.0 days for latency across 4,359 issuers, with a median of 52 filings. The sector medians for 2834 Pharmaceutical Preparations are 6.0 days for cadence and 4.0 days for latency across 526 issuers, with a median of 63.0 filings. The issuer's 88 filings are above the NASDAQ median of 52 and above the sector median of 63.0. The latest filing is dated 2026-11-06 and is of type regulatory_filing. By type, the record holds 2 agm_egm, 4 corporate_news, 3 director_change, 29 directors_dealings, 3 prospectus, 41 regulatory_filing and 6 results filings. ## Auditor The auditor of record is PricewaterhouseCoopers LLP, located in Boston, Massachusetts. The record holds no auditor changes. ## Events and halts The record holds no delisting, listing, or name change lines. The domicile change is not on the record (EDGAR states no dated change of state of incorporation on a filing line). The segment move is not on the record (the exchanges' tier transfers are not EDGAR filings). The halt flag reads listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client_categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's own investor-relations page. The count is 0. ## Open research No openly published research notes were found on the record. The count is 0. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's years sealed are 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001582313.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/XENE (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1582313/000119312526076650/xene-20251231.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/XENE (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/XENE · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp